Ann Dermatol.  2017 Dec;29(6):826-827. 10.5021/ad.2017.29.6.826.

A Type II Segmental Vitiligo Developed under Infliximab Treatment for Ulcerative Colitis

• Ryu TH
• Lee DW
• Choi JE
• Ahn HH
• Kye YC
• Seo SH

• KMID: 2395206
• DOI: http://doi.org/10.5021/ad.2017.29.6.826

Abstract

No abstract available.

MeSH Terms

Colitis, Ulcerative*
Infliximab*
Ulcer*
Vitiligo*
Infliximab

Figure

• 

  Fig. 1 Type II segmental vitiligo showing multiple irregular bordered hypopigmented patches on right facial area: upper medial eyelid and perioral area (A), mainly on mandibular and auricular are (B).

Reference

1. Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, et al. Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol. 2015; 173:641–650.

2. Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016; 2:e000239.

3. Ramírez-Hernández M, Marras C, Martínez-Escribano JA. Infliximab-induced vitiligo. Dermatology. 2005; 210:79–80.

4. Snook JA, de Silva HJ, Jewell DP. The association of autoimmune disorders with inflammatory bowel disease. Q J Med. 1989; 72:835–840.

5. Song MS, Hann SK, Ahn PS, Im S, Park YK. Clinical study of vitiligo. Ann Dermatol. 1994; 6:22–30.